297 related articles for article (PubMed ID: 11724962)
21. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
22. Essential role of factor B of the alternative complement pathway in complement activation and opsonophagocytosis during acute pneumococcal otitis media in mice.
Li Q; Li YX; Stahl GL; Thurman JM; He Y; Tong HH
Infect Immun; 2011 Jul; 79(7):2578-85. PubMed ID: 21502587
[TBL] [Abstract][Full Text] [Related]
23. Study of the optimal reaction conditions for assay of the mouse alternative complement pathway.
Van Dijk H; Rademaker PM; Klerx JP; Willers JM
J Immunol Methods; 1985 Dec; 85(2):233-43. PubMed ID: 4078314
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of complement alternative pathway in mice with Fab antibody to recombinant adipsin/factor D.
Pascual M; Catana E; White T; Spiegelman BM; Schifferli JA
Eur J Immunol; 1993 Jun; 23(6):1389-92. PubMed ID: 8500532
[TBL] [Abstract][Full Text] [Related]
25. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
26. Alternative pathway-mediated rebinding of immune complexes to human red blood cells.
Medof ME; Prince GM
Immunology; 1983 Sep; 50(1):1-9. PubMed ID: 6411608
[TBL] [Abstract][Full Text] [Related]
27. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
28. Regulation of complement functional efficiency by histidine-rich glycoprotein.
Chang NS; Leu RW; Rummage JA; Anderson JK; Mole JE
Blood; 1992 Jun; 79(11):2973-80. PubMed ID: 1375119
[TBL] [Abstract][Full Text] [Related]
29. Complement-dependent B-cell activation by cobra venom factor and other mitogens?
Dukor P; Schumann G; Gisler RH; Dierich M; König W; Hadding U; Bitter-Suermann D
J Exp Med; 1974 Feb; 139(2):337-54. PubMed ID: 4589989
[TBL] [Abstract][Full Text] [Related]
30. Complement abnormalities in multiple myeloma.
Zurlo JJ; Schechter GP; Fries LF
Am J Med; 1989 Oct; 87(4):411-20. PubMed ID: 2679074
[TBL] [Abstract][Full Text] [Related]
31. Recombinant cobra venom factor.
Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
[TBL] [Abstract][Full Text] [Related]
32. Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
Baker PJ; Parker CJ; Osofsky SG
Clin Exp Immunol; 1984 Jan; 55(1):166-76. PubMed ID: 6559107
[TBL] [Abstract][Full Text] [Related]
33. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
Van den Berg CW; Aerts PC; Van Dijk H
J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
[TBL] [Abstract][Full Text] [Related]
34. C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo.
Ruseva MM; Takahashi M; Fujita T; Pickering MC
Clin Exp Immunol; 2014 Apr; 176(1):84-92. PubMed ID: 24279761
[TBL] [Abstract][Full Text] [Related]
35. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
36. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.
Tu AH; Fulgham RL; McCrory MA; Briles DE; Szalai AJ
Infect Immun; 1999 Sep; 67(9):4720-4. PubMed ID: 10456922
[TBL] [Abstract][Full Text] [Related]
37. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
38. Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice.
Cooper PD; Sim RB
Int J Cancer; 1984 May; 33(5):683-7. PubMed ID: 6724743
[TBL] [Abstract][Full Text] [Related]
39. Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes.
Van Dijk H; Rademaker PM; Willers JM
J Immunol Methods; 1980; 36(1):29-39. PubMed ID: 7204994
[TBL] [Abstract][Full Text] [Related]
40. The failure to show a necessary role for C3 in the in vitro antibody response.
Waldmann H; Lachmann PJ
Eur J Immunol; 1975 Mar; 5(3):185-93. PubMed ID: 1086224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
